Table Info

Table 1.

Summary of clinically-significant GLP-1RAs

Drug (commercial name)	Administration	Half-life	Hemoglobin A1c effects	Weight-loss effects	Neuroprotective effects (pre-clinical)
Semaglutide (Rybelsus)	p.o.	1 week	High	High	-
Semaglutide (Ozempic)	s.c.	1 week	High	High	Yes
Liraglutide (Victoza)	s.c.	13 h	High	High	Yes
Dulaglutide (Trulicity)	s.c.	5 days	High	Intermediate	Yes
Terzepetide (Mounjaro)	s.c.	5 days	High	High	-
Exenatide (Byetta)	s.c.	2.4 h	Low	Low	Yes
Lixisenatide (Adlyxin, Lyxumia)	s.c.	3 h	Low	Low	Yes

-: not applicable/no data available

Declarations

Author contributions

Sohum S, AP, MF, MM, AR, RS, and Siddharth S: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing—original draft. Sohum S, AP, MF, MM, AR, RS, Siddharth S, and BLW: Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

DeBusk A, Subramanian PS, Scannell Bryan M, Moster ML, Calvert PC, Frohman LP. Mismatch in supply and demand for neuro-ophthalmic care. J Neuroophthalmol. 2022;42:62–7. [DOI] [PubMed]

Dall TM, Storm MV, Chakrabarti R, Drogan O, Keran CM, Donofrio PD, et al. Supply and demand analysis of the current and future US neurology workforce. Neurology. 2013;81:470–8. [DOI] [PubMed] [PMC]

Feng PW, Ahluwalia A, Feng H, Adelman RA. National trends in the United States eye care workforce from 1995 to 2017. Am J Ophthalmol. 2020;218:128–35. [DOI] [PubMed]

Frohman LP. A profile of neuro-ophthalmic practice around the world. J Neuroophthalmol. 2018;38:47–51. [DOI] [PubMed]

Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation. 2014;1:e40. [DOI] [PubMed] [PMC]

Lee GI, Kim J, Lee D, Park KA, Oh SY, Kong DS, et al. Ganglion cell inner plexiform layer thickness measured by optical coherence tomography to predict visual outcome in chiasmal compression. Sci Rep. 2022;12:14826. [DOI] [PubMed] [PMC]

Nicholson P, Brinjikji W, Radovanovic I, Hilditch CA, Tsang ACO, Krings T, et al. Venous sinus stenting for idiopathic intracranial hypertension: a systematic review and meta-analysis. J Neurointerventional Surg. 2019;11:380–5. [DOI] [PubMed]

Sahel JA, Newman NJ, Yu-Wai-Man P, Vignal-Clermont C, Carelli V, Biousse V, et al. Gene therapies for the treatment of Leber hereditary optic neuropathy. Int Ophthalmol Clin. 2021;61:195–208. [DOI] [PubMed] [PMC]

Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100:432–41. [DOI] [PubMed] [PMC]

10.

Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–31. [DOI] [PubMed] [PMC]

11.

Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol. 2021;12:721135. [DOI] [PubMed] [PMC]

12.

Chowdhury S, Goswami S. GLP1 agonists beyond glycemic control—redefining their role. Int J Diabetes Dev Ctries. 2020;40:461–3. [DOI]

13.

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4:525–36. [DOI] [PubMed]

14.

Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34:S251–7. [DOI] [PubMed] [PMC]

15.

Llewellyn-Smith IJ, Gnanamanickam GJE, Reimann F, Gribble FM, Trapp S. Preproglucagon (PPG) neurons innervate neurochemically identified autonomic neurons in the mouse brainstem. Neuroscience. 2013;229:130–43. [DOI] [PubMed] [PMC]

16.

Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab. 2013;17:413–21. [DOI] [PubMed] [PMC]

17.

Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. [DOI] [PubMed] [PMC]

18.

Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–90. [DOI] [PubMed]

19.

Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740–56. [DOI] [PubMed]

20.

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al.; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51. [DOI] [PubMed]

21.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44. [DOI] [PubMed]

22.

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al.; LEADER Steering Committee; PIONEER 6 Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22. [DOI] [PubMed] [PMC]

23.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–30. [DOI] [PubMed]

24.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al.; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39. [DOI] [PubMed] [PMC]

25.

American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care. 2021;45:S125–43. [DOI] [PubMed]

26.

Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017;60:1390–9. [DOI] [PubMed] [PMC]

27.

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16. [DOI] [PubMed]

28.

Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009;124:113–38. [DOI] [PubMed]

29.

Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh C, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest. 1997;99:2883–9. [DOI] [PubMed] [PMC]

30.

de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008;51:2263–70. [DOI] [PubMed]

31.

Ramracheya R, Chapman C, Chibalina M, Dou H, Miranda C, González A, et al. GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca²⁺ channels. Physiol Rep. 2018;6:e13852. [DOI] [PubMed] [PMC]

32.

Highlights of prescribing information. OZEMPIC (semaglutide) injection, for subcutaneous use [Internet]. FDA; [cited 2023 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf

33.

Jingi AM, Tankeu AT, Ateba NA, Noubiap JJ. Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis. BMC Endocr Disord. 2017;17:63. [DOI] [PubMed] [PMC]

34.

Zheng D, Li N, Hou R, Zhang X, Wu L, Sundquist J, et al. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Med. 2023;21:40. [DOI] [PubMed] [PMC]

35.

Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46:384–90. [DOI] [PubMed]

36.

Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94:1843–52. [DOI] [PubMed] [PMC]

37.

Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Göke B. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil. 2009;21:609–e22. [DOI] [PubMed]

38.

Delgado-Aros S, Vella A, Camilleri M, Low PA, Burton DD, Thomforde GM, et al. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil. 2003;15:435–43. [DOI] [PubMed]

39.

Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ. Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes. 2016;65:34–43. [DOI] [PubMed]

40.

Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front Endocrinol. 2018;9:672. [DOI] [PubMed] [PMC]

41.

Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5:e133429. [DOI] [PubMed] [PMC]

42.

Card JP, Johnson AL, Llewellyn‐Smith IJ, Zheng H, Anand R, Brierley DI, et al. GLP‐1 neurons form a local synaptic circuit within the rodent nucleus of the solitary tract. J Comp Neurol. 2018;526:2149–64. [DOI] [PubMed] [PMC]

43.

Hernandez NS, Ige KY, Mietlicki-Baase EG, Molina-Castro GC, Turner CA, Hayes MR, et al. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. Neuropsychopharmacology. 2018;43:2000–8. [DOI] [PubMed] [PMC]

44.

Lee YS, Jun HS. Anti-Inflammatory Effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016;2016:3094642. [DOI] [PubMed] [PMC]

45.

Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201:59–66. [DOI] [PubMed]

46.

Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, et al. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol. 2014;171:723–34. [DOI] [PubMed] [PMC]

47.

Diz-Chaves Y, Mastoor Z, Spuch C, González-Matías LC, Mallo F. Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases. Int J Mol Sci. 2022;23:9583. [DOI] [PubMed] [PMC]

48.

Trapp S, Richards JE. The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? Curr Opin Pharmacol. 2013;13:964–9. [DOI] [PubMed] [PMC]

49.

Ugleholdt R, Zhu X, Deacon CF, Ørskov C, Steiner DF, Holst JJ. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology. 2004;145:1349–55. [DOI] [PubMed]

50.

Katsurada K, Yada T. Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig. 2016;7:64–9. [DOI] [PubMed] [PMC]

51.

Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol. 1988;271:519–32. [DOI] [PubMed]

52.

Trapp S, Cork SC. PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation. Am J Physiol Regul Integr Comp Physiol. 2015;309:R795–804. [DOI] [PubMed] [PMC]

53.

Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci MN. 2002;18:7–14. [DOI] [PubMed] [PMC]

54.

Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69–72. [DOI] [PubMed]

55.

Schick RR, Zimmermann JP, vorm Walde T, Schusdziarra V. Peptides that regulate food intake: glucagon-like peptide 1-(7–36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1427–35. [DOI] [PubMed]

56.

Dossat AM, Lilly N, Kay K, Williams DL. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J Neurosci Off J Soc Neurosci. 2011;31:14453–7. [DOI] [PubMed] [PMC]

57.

During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173–9. [DOI] [PubMed]

58.

Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes. Neurosci Res. 2006;55:352–60. [DOI] [PubMed]

59.

Schrijvers EMC, Witteman JCM, Sijbrands EJG, Hofman A, Koudstaal PJ, Breteler MM. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology. 2010;75:1982–7. [DOI] [PubMed] [PMC]

60.

Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007;203:293–301. [DOI] [PubMed] [PMC]

61.

McClean PL, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci. 2011;31:6587–94. [DOI] [PubMed] [PMC]

62.

Nordisk. A research study investigating semaglutide in people with early Alzheimer’s disease (EVOKE) [Internet]. HealthPartners Institute; [cited 2023 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04777396

63.

Rosenbloom M. A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer’s disease (EVOKE Plus) [Internet]. HealthPartners Institute; [cited 2023 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04777409

64.

Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol. 2021;12:721135. [DOI] [PubMed] [PMC]

65.

Glotfelty EJ, Delgado TE, Tovar-y-Romo LB, Luo Y, Hoffer B, Olson L, et al. Incretin mimetics as rational candidates for the treatment of traumatic brain injury. ACS Pharmacol Transl Sci. 2019;2:66–91. [DOI] [PubMed] [PMC]

66.

Marlet IR, Ölmestig JNE, Vilsbøll T, Rungby J, Kruuse C. Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischaemic stroke: a systematic review based on pre-clinical studies. Basic Clin Pharmacol Toxicol. 2018;122:559–69. [DOI] [PubMed]

67.

Yang D, Nakajo Y, Iihara K, Kataoka H, Yanamoto H. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res. 2013;1517:104–13. [DOI] [PubMed]

68.

Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci. 2000;20:6309–16. [DOI] [PubMed] [PMC]

69.

Vila M, Jackson-Lewis V, Guégan C, Wu DC, Teismann P, Choi DK, et al. The role of glial cells in Parkinson’s disease. Curr Opin Neurol. 2001;14:483–9. [DOI] [PubMed]

70.

Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol. 2009;202:431–9. [DOI] [PubMed]

71.

Mouhammad ZA, Vohra R, Horwitz A, Thein AS, Rovelt J, Cvenkel B, et al. Glucagon-like peptide 1 receptor agonists – potential game changers in the treatment of glaucoma? Front Neurosci. 2022;16:824054. [DOI] [PubMed] [PMC]

72.

Hao M, Kuang HY, Fu Z, Gao XY, Liu Y, Deng W. Exenatide prevents high-glucose-induced damage of retinal ganglion cells through a mitochondrial mechanism. Neurochem Int. 2012;61:1–6. [DOI] [PubMed]

73.

Sterling JK, Adetunji MO, Guttha S, Bargoud AR, Uyhazi KE, Ross AG, et al. GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Rep. 2020;33:108271. [DOI] [PubMed] [PMC]

74.

Ramos H, Bogdanov P, Sampedro J, Huerta J, Simó R, Hernández C. Beneficial effects of glucagon-like peptide-1 (GLP-1) in diabetes-induced retinal abnormalities: involvement of oxidative stress. Antioxidants. 2020;9:846. [DOI] [PubMed] [PMC]

75.

Yang X, Feng P, Zhang X, Li D, Wang R, Ji C, et al. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology. 2019;158:107748. [DOI] [PubMed]

76.

Gonçalves A, Lin CM, Muthusamy A, Fontes-Ribeiro C, Ambrósio AF, Abcouwer SF, et al. Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood–retinal barrier breakdown and inflammation. Invest Ophthalmol Vis Sci. 2016;57:2584–92. [DOI] [PubMed] [PMC]

77.

Fan Y, Liu K, Wang Q, Ruan Y, Zhang Y, Ye W. Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis. Mol Vis. 2014;20:1557–68. [PubMed] [PMC]

78.

Du Y, Smith MA, Miller CM, Kern TS. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem. 2002;80:771–9. [DOI] [PubMed]

79.

Li N, Zhang X, Zhang M, Wu L, Li C, Pan Y, et al. Associations of genetically determined lipid traits and lipid-modifying agents with the risk of diabetic retinopathy: a Mendelian randomization study. Atherosclerosis. 2023;369:9–16. [DOI] [PubMed]

80.

Hernández C, Bogdanov P, Corraliza L, García-Ramírez M, Solà-Adell C, Arranz JA, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2015;65:172–87. [DOI] [PubMed]

81.

Sampedro J, Bogdanov P, Ramos H, Solà-Adell C, Turch M, Valeri M, et al. New insights into the mechanisms of action of topical administration of GLP-1 in an experimental model of diabetic retinopathy. J Clin Med. 2019;8:339. [DOI] [PubMed] [PMC]

82.

Wei L, Mo W, Lan S, Yang H, Huang Z, Liang X, et al. GLP-1 RA improves diabetic retinopathy by protecting the blood-retinal barrier through GLP-1R-ROCK-p-MLC signaling pathway. J Diabetes Res. 2022;2022:1861940. [DOI] [PubMed] [PMC]

83.

Garczorz W, Gallego-Colon E, Kosowska A, Siemianowicz K, Kłych-Ratuszny A, Woźniak M, et al. Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-α stimulated human retinal pigment epithelial cells. Pharmacol Rep PR. 2019;71:175–82. [DOI] [PubMed]

84.

Al Sabaani N. Exendin-4 inhibits high glucose-induced oxidative stress in retinal pigment epithelial cells by modulating the expression and activation of p⁶⁶Shc. Cutan Ocul Toxicol. 2021;40:175–86. [DOI] [PubMed]

85.

Sohn EH, van Dijk HW, Jiao C, Kok PH, Jeong W, Demirkaya N, et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci U S A. 2016;113:E2655–64. [DOI] [PubMed] [PMC]

86.

Stem MS, Gardner TW. Neurodegeneration in the pathogenesis of diabetic retinopathy: molecular mechanisms and therapeutic implications. Curr Med Chem. 2013;20:3241–50. [DOI] [PubMed] [PMC]

87.

Meyer-Rüsenberg B, Pavlidis M, Stupp T, Thanos S. Pathological changes in human retinal ganglion cells associated with diabetic and hypertensive retinopathy. Graefes Arch Clin Exp Ophthalmol. 2007;245:1009–18. [DOI] [PubMed]

88.

Cui QN, Stein LM, Fortin SM, Hayes MR. The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma. Br J Pharmacol. 2022;179:715–26. [DOI] [PubMed] [PMC]

89.

Zhou H, Ma X, Lin W, Hao M, Yu XY, Li HX, et al. Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1/Parkin-mediated mitophagy in diabetic retinopathy. Front Pharmacol. 2021;1:589114. [DOI] [PubMed] [PMC]

90.

Ma X, Lin W, Lin Z, Hao M, Gao X, Zhang Y, et al. Liraglutide alleviates H₂O₂-induced retinal ganglion cells injury by inhibiting autophagy through mitochondrial pathways. Peptides. 2017;92:1–8. [DOI] [PubMed]

91.

Shu X, Zhang Y, Li M, Huang X, Yang Y, Zeng J, et al. Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling. Neuropharmacology. 2019;153:1–12. [DOI] [PubMed]

92.

Ganesh BS, Chintala SK. Inhibition of reactive gliosis attenuates excitotoxicity-mediated death of retinal ganglion cells. PloS One. 2011;6:e18305. [DOI] [PubMed] [PMC]

93.

Tu Y, Li L, Zhu L, Guo Y, Du S, Zhang Y, et al. Geniposide attenuates hyperglycemia-induced oxidative stress and inflammation by activating the Nrf2 signaling pathway in experimental diabetic retinopathy. Oxid Med Cell Longev. 2021;2021:9247947. [DOI] [PubMed] [PMC]

94.

Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol. 2023;107:215–20. [DOI] [PubMed]

95.

Mead B, Tomarev S. Evaluating retinal ganglion cell loss and dysfunction. Exp Eye Res. 2016;151:96–106. [DOI] [PubMed] [PMC]

96.

Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7. [DOI] [PubMed] [PMC]

97.

Tang Y, Chen Y, Chen D. The heterogeneity of astrocytes in glaucoma. Front Neuroanat. 2022;16:995369. [DOI] [PubMed] [PMC]

98.

Tezel G, Wax MB. Glial modulation of retinal ganglion cell death in glaucoma. J Glaucoma. 2003;12:63–8. [DOI] [PubMed]

99.

Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;20:570–7. Erratum in: Trends Neurosci. 1998;21:80. [DOI] [PubMed]

100.

Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nat Med. 2018;24:931–8. [DOI] [PubMed] [PMC]

101.

Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomised clinical trial. Brain. 2023;146:1821–30. [DOI] [PubMed] [PMC]

102.

Alvarez E, Roncero I, Chowen JA, Thorens B, Blázquez E. Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem. 1996;66:920–7. [DOI] [PubMed]

103.

Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM, et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017;9:eaan0972. [DOI] [PubMed]

104.

Mollan SP, Tahrani AA, Sinclair AJ. The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight. Neurol Clin Pract. 2021;11:e504–7. [DOI] [PubMed] [PMC]

105.

NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311:1641–51. [DOI] [PubMed] [PMC]

106.

Ng E, Shaw JE, Wood A, Maple-Brown LJ, Hare MJ. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes. Aust J Gen Pract. 2022;51:513–8. [DOI] [PubMed]

107.

Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239–46. [DOI] [PubMed]

108.

Muscogiuri G, DeFronzo RA, Gastaldelli A, Holst JJ. Glucagon-like peptide-1 and the central/peripheral nervous system: crosstalk in diabetes. Trends Endocrinol Metab. 2017;28:88–103. [DOI] [PubMed]